236 related articles for article (PubMed ID: 12491512)
21. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
22. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
Laurencet FM; Zulian GB; Guetty-Alberto M; Iten PA; Betticher DC; Alberto P
Br J Cancer; 1999 Mar; 79(7-8):1215-9. PubMed ID: 10098762
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
[TBL] [Abstract][Full Text] [Related]
24. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
31. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
[TBL] [Abstract][Full Text] [Related]
32. Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Robak T; Szmigielska-Kapłon A; Błoński JZ; Kasznicki M; Chojnowski K
Chemotherapy; 2005 Aug; 51(5):247-51. PubMed ID: 16088121
[TBL] [Abstract][Full Text] [Related]
33. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
34. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Giles FJ; Shi GG; Cortes JE; Thomas D; Keating AR; Kantarjian HM; Keating MJ; O'Brien SM
Cancer Chemother Pharmacol; 2003 Sep; 52(3):223-8. PubMed ID: 12783199
[TBL] [Abstract][Full Text] [Related]
35. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
36. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
37. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
Van Den Neste E; Michaux L; Layios N; Costantini S; Francart J; Lambert C; Sonet A; André M; Robert A; Ferrant A
Ann Hematol; 2004 Jun; 83(6):356-63. PubMed ID: 15024607
[TBL] [Abstract][Full Text] [Related]
38. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
40. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]